Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 4/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.35 |
| ▸ | CCR3 | P51677 | 1/20 | 0.34 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | LDHB | P07195 | 1/20 | 0.33 |
| ▸ | MDM4 | O15151 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6175702 | 0.89 | KCNH2 (0.39) | KCNH2BRD4CREBBPKCNN4CCR3 | |
| SCHEMBL2658681 | 0.89 | SLC6A3 (0.40) | KCNH2MDM4MDM2 | |
| SCHEMBL6172615 | 0.88 | SMURF1 (0.37) | KCNH2CCR3LDHALDHBMDM4 | |
| SCHEMBL6175163 | 0.88 | SLC6A3 (0.41) | KCNH2MDM4MDM2 | |
| SCHEMBL6173445 | 0.84 | KCNH2 (0.43) | KCNH2MDM4MDM2ALDH1A1 | |
| SCHEMBL2657730 | 0.81 | KCNH2 (0.65) | KCNH2 | |
| SCHEMBL6174536 | 0.80 | KCNH2 (0.42) | KCNH2ALDH1A1 | |
| SCHEMBL2648102 | 0.79 | KCNH2 (0.45) | KCNH2BRD4CREBBPRENALDH1A1 | |
| SCHEMBL6174485 | 0.77 | KCNH2 (0.39) | KCNH2MDM2CNR2 | |
| SCHEMBL6173291 | 0.77 | SLC6A3 (0.39) | KCNH2LDHALDHBMDM4MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1311504-B1 | TETRAZOLYL-PHENYL ACETAMIDE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | EP | disclosed |
| US-6441180-B1 | TO INCREASE INSULIN SECRETION, WHICH MAKES THEM USEFUL FOR TREATING TYPE II DIABETES | HOFFMANN-LA ROCHE INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020065275-A1 | Tetrazolyl-phenyl actamide glucokinase activators | SIDDURI ACHYUTHARAO (US) | 2002-05-30 | — | — | US | disclosed |
| US-6388088-B1 | ANTIDIABETIC AGENTS | HOFFMAN-LA ROCHE INC. | 2002-05-14 | — | — | US | disclosed |
| US-6369232-B1 | ANTIDIABETIC AGENTS | HOFFMANN-LA ROCHE INC. | 2002-04-09 | — | — | US | disclosed |
| US-20020035267-A1 | Tetrazolyl-phenyl acetamide glucokinase activators | SIDDURI ACHYUTHARAO (US) | 2002-03-21 | — | — | US | disclosed |
| US-20020035266-A1 | Tetrazolyl-phenyl acetamide glucokinase activators | SIDDURI ACHYUTHARAO (US) | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035267-A1 | Tetrazolyl-phenyl acetamide glucokinase activators | GCKR, GCK, PCK1 | KCNH2 1679/4885BRD4 1970/4885CREBBP 266/4885 |
| US-20020035266-A1 | Tetrazolyl-phenyl acetamide glucokinase activators | GCKR, GCK, PCK1 | KCNH2 1679/4885BRD4 1970/4885CREBBP 266/4885 |
| US-20020065275-A1 | Tetrazolyl-phenyl actamide glucokinase activators | GCKR, GCK, PFKL | KCNH2 1466/4885BRD4 2898/4885CREBBP 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.